Accounts Receivable, after Allowance for Credit Loss, Current of BIO-TECHNE Corp from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
BIO-TECHNE Corp quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • BIO-TECHNE Corp Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $184,614,000, a 15% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

BIO-TECHNE Corp Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $184,614,000 -$33,326,000 -15% 31 Dec 2025 10-Q 04 Feb 2026 2026 Q2
Q3 2025 $183,897,000 -$39,791,000 -18% 30 Sep 2025 10-Q 05 Nov 2025 2026 Q1
Q2 2025 $206,876,000 -$34,518,000 -14% 30 Jun 2025 10-Q 04 Feb 2026 2026 Q2
Q1 2025 $237,140,000 +$9,253,000 +4.1% 31 Mar 2025 10-Q 08 May 2025 2025 Q3
Q4 2024 $217,940,000 +$10,489,000 +5.1% 31 Dec 2024 10-Q 06 Feb 2025 2025 Q2
Q3 2024 $223,688,000 +$19,118,000 +9.3% 30 Sep 2024 10-Q 05 Nov 2024 2025 Q1
Q2 2024 $241,394,000 +$22,926,000 +10% 30 Jun 2024 10-K 22 Aug 2025 2025 FY
Q1 2024 $227,887,000 +$11,472,000 +5.3% 31 Mar 2024 10-Q 06 May 2024 2024 Q3
Q4 2023 $207,451,000 +$22,688,000 +12% 31 Dec 2023 10-Q 07 Feb 2024 2024 Q2
Q3 2023 $204,570,000 +$30,396,000 +17% 30 Sep 2023 10-Q 07 Nov 2023 2024 Q1
Q2 2023 $218,468,000 +$23,920,000 +12% 30 Jun 2023 10-K 22 Aug 2024 2024 FY
Q1 2023 $216,415,000 +$14,320,000 +7.1% 31 Mar 2023 10-Q 08 May 2023 2023 Q3
Q4 2022 $184,763,000 +$31,867,000 +21% 31 Dec 2022 10-Q 07 Feb 2023 2023 Q2
Q3 2022 $174,174,000 +$26,626,000 +18% 30 Sep 2022 10-Q 07 Nov 2022 2023 Q1
Q2 2022 $194,548,000 +$49,163,000 +34% 30 Jun 2022 10-K 23 Aug 2023 2023 FY
Q1 2022 $202,095,000 +$44,305,000 +28% 31 Mar 2022 10-Q 09 May 2022 2022 Q3
Q4 2021 $152,896,000 +$24,653,000 +19% 31 Dec 2021 10-Q 07 Feb 2022 2022 Q2
Q3 2021 $147,548,000 +$24,913,000 +20% 30 Sep 2021 10-Q 08 Nov 2021 2022 Q1
Q2 2021 $145,385,000 +$22,851,000 +19% 30 Jun 2021 10-K 24 Aug 2022 2022 FY
Q1 2021 $157,790,000 +$40,338,000 +34% 31 Mar 2021 10-Q 07 May 2021 2021 Q3
Q4 2020 $128,243,000 +$16,490,000 +15% 31 Dec 2020 10-Q 08 Feb 2021 2021 Q2
Q3 2020 $122,635,000 -$89,000 -0.07% 30 Sep 2020 10-Q 09 Nov 2020 2021 Q1
Q2 2020 $122,534,000 -$14,932,000 -11% 30 Jun 2020 10-K 25 Aug 2021 2021 FY
Q1 2020 $117,452,000 -$16,475,000 -12% 31 Mar 2020 10-Q 11 May 2020 2020 Q3
Q4 2019 $111,753,000 -$1,530,000 -1.4% 31 Dec 2019 10-Q 06 Feb 2020 2020 Q2
Q3 2019 $122,724,000 +$7,971,000 +6.9% 30 Sep 2019 10-Q 06 Nov 2019 2020 Q1
Q2 2019 $137,466,000 +$17,170,000 +14% 30 Jun 2019 10-K 26 Aug 2020 2020 FY
Q1 2019 $133,927,000 +$24,168,000 +22% 31 Mar 2019 10-Q 07 May 2019 2019 Q3
Q4 2018 $113,283,000 +$14,785,000 +15% 31 Dec 2018 10-Q 07 Feb 2019 2019 Q2
Q3 2018 $114,753,000 +$7,428,000 +6.9% 30 Sep 2018 10-Q 07 Nov 2018 2019 Q1
Q2 2018 $120,296,000 +$3,466,000 +3% 30 Jun 2018 10-K/A 06 Nov 2019 2019 FY
Q1 2018 $109,759,000 -$8,576,000 -7.2% 31 Mar 2018 10-Q 09 May 2018 2018 Q3
Q4 2017 $98,498,000 -$5,870,000 -5.6% 31 Dec 2017 10-Q 08 Feb 2018 2018 Q2
Q3 2017 $107,325,000 -$2,488,000 -2.3% 30 Sep 2017 10-Q 09 Nov 2017 2018 Q1
Q2 2017 $116,830,000 +$23,437,000 +25% 30 Jun 2017 10-K 27 Aug 2018 2018 FY
Q1 2017 $118,335,000 +$31,179,000 +36% 31 Mar 2017 10-Q 10 May 2017 2017 Q3
Q4 2016 $104,368,000 +$38,233,000 +58% 31 Dec 2016 10-Q 09 Feb 2017 2017 Q2
Q3 2016 $109,813,000 +$38,898,000 +55% 30 Sep 2016 10-Q 09 Nov 2016 2017 Q1
Q2 2016 $93,393,000 +$23,359,000 +33% 30 Jun 2016 10-K 07 Sep 2017 2017 FY
Q1 2016 $87,156,000 +$21,271,000 +32% 31 Mar 2016 10-Q 10 May 2016 2016 Q3
Q4 2015 $66,135,000 +$8,921,000 +16% 31 Dec 2015 10-Q 09 Feb 2016 2016 Q2
Q3 2015 $70,915,000 +$10,046,000 +17% 30 Sep 2015 10-Q 09 Nov 2015 2016 Q1
Q2 2015 $70,034,000 +$15,033,000 +27% 30 Jun 2015 10-K 29 Aug 2016 2016 FY
Q1 2015 $65,885,000 +$17,384,000 +36% 31 Mar 2015 10-Q 11 May 2015 2015 Q3
Q4 2014 $57,214,000 +$18,908,000 +49% 31 Dec 2014 10-Q 09 Feb 2015 2015 Q2
Q3 2014 $60,869,000 +$18,629,000 +44% 30 Sep 2014 10-Q 10 Nov 2014 2015 Q1
Q2 2014 $55,001,000 +$16,818,000 +44% 30 Jun 2014 10-K 31 Aug 2015 2015 FY
Q1 2014 $48,501,000 +$10,363,000 +27% 31 Mar 2014 10-Q 12 May 2014 2014 Q3
Q4 2013 $38,306,000 +$6,119,000 +19% 31 Dec 2013 10-Q 04 Feb 2014 2014 Q2
Q3 2013 $42,240,000 +$7,121,000 +20% 30 Sep 2013 10-Q 12 Nov 2013 2014 Q1
Q2 2013 $38,183,000 +$2,515,000 +7.1% 30 Jun 2013 10-K 29 Aug 2014 2014 FY
Q1 2013 $38,138,000 -$976,000 -2.5% 31 Mar 2013 10-Q 10 May 2013 2013 Q3
Q4 2012 $32,187,000 -$164,000 -0.51% 31 Dec 2012 10-Q 11 Feb 2013 2013 Q2
Q3 2012 $35,119,000 +$1,027,000 +3% 30 Sep 2012 10-Q 09 Nov 2012 2013 Q1
Q2 2012 $35,668,000 -$246,000 -0.68% 30 Jun 2012 10-K 29 Aug 2013 2013 FY
Q1 2012 $39,114,000 +$3,560,000 +10% 31 Mar 2012 10-Q 10 May 2012 2012 Q3
Q4 2011 $32,351,000 +$4,123,000 +15% 31 Dec 2011 10-Q 07 Feb 2012 2012 Q2
Q3 2011 $34,092,000 +$3,073,000 +9.9% 30 Sep 2011 10-Q 09 Nov 2011 2012 Q1
Q2 2011 $35,914,000 +$5,064,000 +16% 30 Jun 2011 10-K 29 Aug 2012 2012 FY
Q1 2011 $35,554,000 31 Mar 2011 10-Q 10 May 2011 2011 Q3
Q4 2010 $28,228,000 31 Dec 2010 10-Q 09 Feb 2011 2011 Q2
Q3 2010 $31,019,000 30 Sep 2010 10-Q 09 Nov 2010 2011 Q1
Q2 2010 $30,850,000 30 Jun 2010 10-K 29 Aug 2011 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.